Bioventus Inc. · NASDAQ:BVS
Bioventus — Merger or Acquisition (July 2021)
11 slides from Bioventus's merger presentation, Jul 29, 2021
Slide 1: Bioventus’ Acquisition of Misonix
Bioventus’ Acquisition of Misonix July 29, 2021
Slide 2: Transaction Details
Innovations For Active Healing Transaction Details • In the transaction, Misonix stockholders may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix common stock they hold, subject to proration based on an a
Slide 3: Bioventus At a Glance Key Investment Highlights
Innovations For Active Healing Bioventus At a Glance Key Investment Highlights • Bioventus offers clinically differentiated, cost efficient, and minimally invasive treatments that engage and enhance 1. Broad customer reach and the body’s natural healing process market access – #2 in HA(1) in the U.S
Slide 4: Misonix extends Bioventus’ leadership across key franchises and expands the breadth and depth of offerings
Innovations For Active Healing Misonix extends Bioventus’ leadership across key franchises and expands the breadth and depth of offerings Ultrasonic medical devices for the precise removal of hard and soft tissue Differentiated spine surgical / wound platform driving sustainable double-digit revenue
Slide 5: Surgical Wound
Innovations For Active Healing Surgical Wound ~$40M FY21 Revenue ~$34M FY21 Revenue Bone Resection Tumor Aspiration Wound Debridement Skin Substitutes drive unit shared across all handheld products Product • Differentiated technology that • Precise tissue removal for • Necrotic tissue and biofilm is
Slide 6: Platform technology that enables additional organic and inorganic expansion opportunities
Innovations For Active Healing + Platform technology that enables additional organic and inorganic expansion opportunities Highly complementary product offerings leveraging combined sales infrastructure to drive revenue acceleration Accelerates top-line growth with strong financial returns Expected
Slide 7: The “New” Bioventus
Innovations For Active Healing The “New” Bioventus Pain Treatments Restorative Therapies Surgical Solutions TalisMann Products Wound Surgical Expected Pro Forma ~$215M ~$170M ~$115M ’21 BVS Rev. $350M Global Bone Healing $2.7B US Orthobiologics $2B Global HA $1.75B Global Rehabilitation $600M Bone R
Slide 8: A Significant Synergy Opportunity
Innovations For Active Healing A Significant Synergy Opportunity Cost Synergies Growth Acceleration Bioventus expects $20M expected annualized Bioventus expects significant potential cost synergies by end of 2023 revenue synergies Comprehensive coverage of entire wound Improved scale of the combined
Slide 9: Compelling Shareholder Value Creation
Innovations For Active Healing Compelling Shareholder Value Creation Transformational Scale and Robust Growth • Approximately $500M of forecasted pro forma 2021 revenues expected by Bioventus to grow double-digits • Enhanced sales force leverage in both spine surgical and wound care Significant Syne
Slide 10: Preliminary Bioventus Q2 ‘21 Revenue & FY21 Guidance Update
Innovations For Active Healing Preliminary Bioventus Q2 ‘21 Revenue & FY21 Guidance Update Preliminary Q2 2021 Revenue Updated Full Year 2021 Revenue Guidance +86%-90% y.o.y. +26%-29% y.o.y. $108-110M $405-415M Organic Revenue Growth* Organic Revenue Growth* +66%-69% y.o.y. +16%-18% y.o.y. * Organic
Slide 11: Disclaimer
Innovations For Active Healing Disclaimer Additional Information In connection with the proposed transaction, Bioventus and Misonix plan to file with the Securities and Exchange Commission (the “SEC”) and mail or otherwise provide to their respective stockholders a joint proxy statement/prospectus a